JP6348567B2 - マイクロエマルジョン局所送達プラットフォーム - Google Patents

マイクロエマルジョン局所送達プラットフォーム Download PDF

Info

Publication number
JP6348567B2
JP6348567B2 JP2016501962A JP2016501962A JP6348567B2 JP 6348567 B2 JP6348567 B2 JP 6348567B2 JP 2016501962 A JP2016501962 A JP 2016501962A JP 2016501962 A JP2016501962 A JP 2016501962A JP 6348567 B2 JP6348567 B2 JP 6348567B2
Authority
JP
Japan
Prior art keywords
oil
api
pharmaceutical composition
surfactants
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016501962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512562A (ja
JP2016512562A5 (enExample
Inventor
エイ ワッセル，ロナルド
エイ ワッセル，ロナルド
ジョージ モンダレク，ファディー
ジョージ モンダレク，ファディー
エイ ファージョ，ラファル
エイ ファージョ，ラファル
ビー キャンバオ，アレクサンダー
ビー キャンバオ，アレクサンダー
ジェイ ヌーノ，ディディエ
ジェイ ヌーノ，ディディエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyecro LLC
Original Assignee
Eyecro LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyecro LLC filed Critical Eyecro LLC
Publication of JP2016512562A publication Critical patent/JP2016512562A/ja
Publication of JP2016512562A5 publication Critical patent/JP2016512562A5/ja
Application granted granted Critical
Publication of JP6348567B2 publication Critical patent/JP6348567B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016501962A 2013-03-14 2014-03-13 マイクロエマルジョン局所送達プラットフォーム Active JP6348567B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784005P 2013-03-14 2013-03-14
US61/784,005 2013-03-14
PCT/US2014/025773 WO2014160079A1 (en) 2013-03-14 2014-03-13 Microemulsion topical delivery platform

Publications (3)

Publication Number Publication Date
JP2016512562A JP2016512562A (ja) 2016-04-28
JP2016512562A5 JP2016512562A5 (enExample) 2017-02-23
JP6348567B2 true JP6348567B2 (ja) 2018-06-27

Family

ID=50628949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501962A Active JP6348567B2 (ja) 2013-03-14 2014-03-13 マイクロエマルジョン局所送達プラットフォーム

Country Status (12)

Country Link
US (2) US8968775B2 (enExample)
EP (1) EP2968139B1 (enExample)
JP (1) JP6348567B2 (enExample)
CN (1) CN105451718B (enExample)
AU (1) AU2014244154B2 (enExample)
CA (1) CA2905023C (enExample)
DK (1) DK2968139T3 (enExample)
ES (1) ES2673009T3 (enExample)
PL (1) PL2968139T3 (enExample)
PT (1) PT2968139T (enExample)
TR (1) TR201808197T4 (enExample)
WO (1) WO2014160079A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2448494T3 (es) 2006-07-13 2014-03-14 Achillion Pharmaceuticals, Inc. Péptidos de 4-amino-4-oxobutanoilo en calidad de inhibidores de la replicación viral
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
WO2017127306A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
DK3266446T3 (en) * 2016-07-07 2019-02-11 Salvat Lab Sa Eye preparation comprising castor oil and medium chain triglyceride
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
KR102652605B1 (ko) * 2017-08-27 2024-03-28 로드스 테크놀로지즈 안과 질환 치료를 위한 약학제적 조성물
US11583497B2 (en) 2017-11-14 2023-02-21 The Schepens Eye Research Institute, Inc. Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery
JP7569336B2 (ja) 2019-06-11 2024-10-17 サイファイ エス．ピー．エー． マイクロエマルション組成物
JP6622950B1 (ja) * 2019-07-08 2019-12-18 株式会社Moresco マイクロエマルションを調製するための組成物、マイクロエマルション、これらの製造方法、及びマイクロエマルションの利用
JP7785295B2 (ja) * 2020-11-19 2025-12-15 学校法人日本大学 網膜循環障害及び網膜神経血管連関障害の改善用又は予防用点眼剤
US20240408010A1 (en) * 2021-10-01 2024-12-12 University Of South Africa A Nano Emulsified Phyto-Drug For Transdermal Treatment of Diabetes
WO2025034554A1 (en) * 2023-08-04 2025-02-13 Ads Therapeutics Llc Compositions and methods for delivery of ophthalmological actives
IL327899A (en) 2023-10-23 2026-06-01 Inmed Pharmaceuticals Inc Compositions and methods for use of cannabinol compounds in neuroprotection
WO2026085060A1 (en) * 2024-10-15 2026-04-23 Virginia Commonwealth University Ppara agonist loaded microemulsion and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US7569612B1 (en) * 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
US20090082470A1 (en) * 2007-09-24 2009-03-26 Rafal Farjo Stat3 inhibiting compositions and methods
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
AU2012214146A1 (en) * 2011-02-11 2013-08-29 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof

Also Published As

Publication number Publication date
EP2968139B1 (en) 2018-05-23
AU2014244154A1 (en) 2015-09-24
WO2014160079A1 (en) 2014-10-02
PT2968139T (pt) 2018-06-18
US9149453B2 (en) 2015-10-06
PL2968139T3 (pl) 2018-10-31
CN105451718A (zh) 2016-03-30
EP2968139A1 (en) 2016-01-20
US8968775B2 (en) 2015-03-03
CA2905023A1 (en) 2014-10-02
AU2014244154B2 (en) 2018-08-09
CN105451718B (zh) 2018-09-28
ES2673009T3 (es) 2018-06-19
DK2968139T3 (en) 2018-06-25
US20150164846A1 (en) 2015-06-18
JP2016512562A (ja) 2016-04-28
CA2905023C (en) 2019-10-15
US20140275263A1 (en) 2014-09-18
TR201808197T4 (tr) 2018-07-23

Similar Documents

Publication Publication Date Title
EP2968139B1 (en) Microemulsion topical delivery platform
JP2016512562A5 (enExample)
JP7496778B2 (ja) チモロールを含む医薬組成物
JP7547411B2 (ja) 局所用シクロスポリン含有製剤およびその使用
JP7353292B2 (ja) ネビボロールを含む医薬組成物
JPH0899867A (ja) 眼科用ビヒクルとして有用な水中油型ナノエマルジョンおよびその調製法
US20210085603A1 (en) Microemulsion for opthalmic drug delivery
JP2017519813A (ja) 局所製剤およびその使用
JP2018532809A (ja) 局所製剤およびその使用
JP2018532809A5 (enExample)
KR20150000405A (ko) 난용성 의약품의 수중유적형 에멀젼 조성물 및 이의 제조방법
CN116898800A (zh) 无防腐剂的眼科药物乳剂及其应用
KR101151235B1 (ko) 나노에멀젼 형태의 안과용 조성물
US20140302099A1 (en) Ophthalmic Composition Containing Cyclosporine And method For Preparing Same
Acharya Development and Evaluation of Liquid Crystalline Cubogel for Ocular Delivery of Anti-glaucoma Agents
HK40044057A (en) Pharmaceutical compositions comprising nebivolol
HK40044057B (en) Pharmaceutical compositions comprising nebivolol
WO2004069822A1 (ja) ステロイド副作用抑制組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180531

R150 Certificate of patent or registration of utility model

Ref document number: 6348567

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250